NCT01798901 - AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 17, 2013

Primary Completion Date

February 19, 2015

Study Completion Date

February 19, 2015

Conditions

Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid Leukemia

Interventions

DRUG

HDAC inhibitor AR-42

Given PO

DRUG

decitabine

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (3)

43205

Nationwide Children's Hospital, Columbus

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

45229

Cincinnati Children's Hospital, Cincinnati

All Listed Sponsors

lead

Alison Walker

OTHER